Last Price$8.63NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/16/22

Today's Change+0.01(0.12%)
Bid (Size)$8.23 (1)
Ask (Size)$9.30 (10)
Day Low / High$8.46 - 8.82
Volume479.3 K

First Patient Dosed in Mid-Stage Study of Alector, GlaxoSmithKline's AL001 to Treat Amyotrophic Lateral Sclerosis

12:01PM ET 9/09/2021 MT Newswires
Alector (ALEC) reported Thursday that the first patient has been dosed in a phase 2 study evaluating AL001, which it is developing with GlaxoSmithKline (GSK), to treat patients with amyotrophic lateral sclerosis, a progressive neurodegenerative disorder.

The study is expected to enroll about 45 adult participants with a C9orf72 mutation, the clinical-stage drugmaker said. The primary endpoint is safety, tolerability, pharmacokinetics and pharmacodynamics of AL001.

Shares of Alector are up 7% in late morning trading, while shares of GlaxoSmithKline are down more than 1%.

Price: 23.36, Change: +1.70, Percent Change: +7.88